~~<i id='8A228F2FE0'><strike id='8A228F2FE0'><tt id='8A228F2FE0'><pre id='8A228F2FE0'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：leisure time 2025-09-06 07:20:53 Page View：8253

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： IRA could hurt research into orphan drugs for rare diseases
Next article： Affirmative action in medical school literally saved lives

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

Attacks on the drug industry will lead to fewer breakthroughs

TedW.Love,sittingintheplaidshirt,withhisfamilyin1964CourtesyTedLoveIwasborninAlabamaintheJimCrowSout

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

Humana, CVS hope to turn members into patients at clinics

AdobeBothHumanaandCVSHealthonWednesdaytoutedplanstoaggressivelyscaletheirprimarycareclinicsforsenior